Loading...
Loading...
The rise of weight loss drugs like Wegovy and Mounjaro by Novo Nordisk NVO is leading to new product developments across various sectors. What Happened : Companies from food and beverage to fitness are adapting to the increased demand for these drugs, hoping to capitalize on shifting consumer habits, CNBC reported on Friday. DSM Firmenich is exploring nutritional supplements to complement the effects of these weight loss drugs.
CEO Dimitri de Vreeze told CNBC that this move is a natural progression for the industry. "If you go to weight loss and you're successful, you move to the health, nutrition, lifestyle counter, because you basically want to continue what you have. There we come into play," de Vreeze told.
Swiss food giant Nestle has announced a new frozen food range aimed at users of GLP-1 drugs. CEO Mark Schneider emphasized that while weight loss drugs change consumer behaviors, nutritional needs remain constant. Danone CEO Antoine de Saint-Affrique also sees GLP-1 drugs as complementary to their nutritional products, potentially increasing demand.
Analysts remain cautious about the long-term impact of these drugs. Barclays analysts suggest that while GLP-1 drugs could substitute certain food products, they might also increase demand for healthier options. Pharmaceutical packaging companies and even airlines could benefit from the growing weight loss drug market.
However, the full impact on various industries remains to be seen. See Also: Ross Ge.